Longitudinal Follow-Up of Fibrosis-4 in Patients at Risk of Metabolic Dysfunction-Associated Steatotic Liver Disease Receiving Low-Dose Methotrexate Treatment
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Noninvasive liver fibrosis tests, like the fibrosis-4 (FIB-4) score, can predict fibrosis severity. FIB-4 is widely used for monitoring liver disease, including metabolic dysfunction-associated steatotic liver disease (MASLD).
Area Of Science
- Hepatology
- Biomarkers
- Liver Disease Diagnostics
Background
- Liver biopsy is invasive; noninvasive tests are needed for fibrosis assessment.
- The fibrosis-4 (FIB-4) score was initially developed for HIV/HCV co-infected patients.
- FIB-4 is increasingly used for monitoring liver fibrosis in metabolic dysfunction-associated steatotic liver disease (MASLD).
Purpose Of The Study
- To review the role of noninvasive liver fibrosis tests.
- To highlight the utility of the FIB-4 score in clinical practice.
- To discuss FIB-4's application in MASLD monitoring.
Main Methods
- Review of existing literature on liver fibrosis tests.
- Analysis of FIB-4 score's application and validation.
- Discussion of clinical relevance in MASLD patients.
Main Results
- Noninvasive tests show promise in predicting fibrosis severity.
- FIB-4 score is a widely adopted tool for liver fibrosis monitoring.
- FIB-4 aids in managing patients with MASLD.
Conclusions
- Noninvasive liver fibrosis tests, particularly FIB-4, are valuable tools.
- FIB-4 offers a practical approach to monitoring liver fibrosis.
- Continued research supports the use of FIB-4 in MASLD management.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
